Ethel Weld, MD

Protocol chair, IMPAACT 2005
Protocol vice-chair, IMPAACT 2022
Member, Clinical Pharmacology Advisory Group of the ACTG Laboratory Steering Committee (2018-Present)
Member, ACTG Antiretroviral Therapy Strategies Transformative Science Group Less Frequent Dosing ART Working Group
Member, Pharmacology Core, HPTN Laboratory Core
Member, TB in Pregnancy Working Group
Protocol pharmacologist for HPTN 086, IMPAACT CAP 544, IMPAACT CAP 543

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1...

Johns Hopkins University Baltimore-India Clinical Trials Unit